Evotec AG has achieved its first milestones in its multi-target drug discovery collaboration with UCB in the field of immunology. The milestones included the progression of certain projects into hit-to-lead and lead optimization. Financial terms were not disclosed.   Under the collaboration, entered in October 2011, Evotec receives research payments and preclinical, clinical, and sales milestones, as well as royalties on product sales.   Dr. Mario Polywka, chief operating officer of Evotec, said...